Teligent, Inc. (TLGT) News



Teligent, Inc. (TLGT)

Today's Latest Price: $1.18 USD

0.09 (-7.09%)

Updated Jan 22 4:00pm

Add TLGT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

StocksNews Articles for TLGT

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TLGT News From Around the Web

Below are the latest news stories about Teligent Inc that investors may wish to consider to help them evaluate TLGT as an investment opportunity.

Teligent (NASDAQ:TLGT) Releases Earnings Results, Misses Expectations By $0.61 EPS

Teligent (NASDAQ:TLGT) released its quarterly earnings results on Wednesday. The company reported ($2.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.61), Fidelity Earnings reports. NASDAQ TLGT opened at $0.75 on Friday. The stock has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.08 and a beta of […]

Transcript Daily | January 1, 2021

Teligent EPS beats by $1.06, beats on revenue

Teligent (TLGT): Q3 Non-GAAP EPS of -$0.42 beats by $1.06; GAAP EPS of -$0.08 beats by $2.00.Revenue of $14.34M (-22.4% Y/Y) beats by $0.77M.Press Release...

Seeking Alpha | December 31, 2020

Teligent, Inc. Announces Third Quarter 2020 Results

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.Financial HighlightsThird Quarter 2020 vs. Second Quarter 2020 * Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand for US topical products * Gross profit of $0.1 million, a decrease of $2.4 million driven by additional inventory reserves and write offs * Product development and research expenses of $2.4 million, an increase of $0.5 million due to API write offs for development programs not being pursued * Selling, general and administrative expenses of $6.5 million, an increase of $1.6 million or 31% driven by increased...

Yahoo | December 31, 2020

$TLGT PT 3-5.75 and higher by Jan 5th to Jan 21st for NASDAQ:TLGT by Rocky88888888888

Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid …

TradingView | December 14, 2020

Why Is It Moving? Analyzing The Upward Movement in Teligent's Stock Today

The Price And Volume Action In Teligent's Stock Today Teligent (NASDAQ: TLGT) is currently up 67.3% to a price of $1.12. Monday the stock has been …

Benzinga | December 14, 2020

The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis T...

Benzinga | November 3, 2020

Teligent (NASDAQ:TLGT) Shares Gap Up to $1.05

Teligent Inc (NASDAQ:TLGT)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $1.05, but opened at $1.33. Teligent shares last traded at $0.80, with a volume of 270,178 shares. A number of analysts have recently weighed in on the company. ValuEngine upgraded Teligent from a “hold” rating […]

Zolmax News | October 24, 2020

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

Scheduled to Reconvene on November 11, 2020Company Urgently Encourages Stockholders to Vote BUENA, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Teligent,…

GlobeNewswire | October 22, 2020

The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences o...

Benzinga | October 7, 2020

TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TLGT #TLGT--TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc.

Business Wire | October 2, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6614 seconds.